Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V118 Formulation C vaccine in healthy adults
NCT06611033Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Sep 2024
- Primary completion
- Jan 2026
- Modality
- Split/Subunit Vaccines
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of V118 in pneumococcal disease (3 arms), sponsored by Merck & Co. Primary endpoints: Number of Participants with Solicited Injection Site Adverse Events at 7 days, Number of Participants with Solicited Systemic Adverse Events at 7 days and 5 more. Started Sep 2024; status: completed.
02
Drugs
V118
03
Conditions
pneumococcal disease
Beyond the preview
Go deeper on NCT06611033.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06611033.